We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Cancer Risk Assessed by Circulating Protein Biomarker Panel

By LabMedica International staff writers
Posted on 10 Aug 2018
Print article
Image: A photomicrograph of squamous-cell carcinoma, a type of non-small-cell carcinoma of the lung, from a fine needle aspiration specimen (Photo courtesy of Nephron).
Image: A photomicrograph of squamous-cell carcinoma, a type of non-small-cell carcinoma of the lung, from a fine needle aspiration specimen (Photo courtesy of Nephron).
The question has been asked whether a risk prediction model based on circulating protein biomarkers improve on a traditional risk prediction model for lung cancer and the current USA screening criteria.

Current screening criteria for lung cancer risk assessments often miss a large proportion of cases. It has recently been suggested that a panel of specific circulating protein biomarkers may improve lung cancer risk assessment and may be used to define eligibility for computed tomography screening.

A large international consortium of scientists led by International Agency for Research on Cancer (Lyon, France) collected prediagnostic samples from 108 ever-smoking patients with lung cancer diagnosed within one year after blood collection and samples from 216 smoking-matched controls from the Carotene and Retinol Efficacy Trial (CARET) cohort. The samples were used to develop a biomarker risk score based on four proteins (cancer antigen 125 [CA125], carcinoembryonic antigen [CEA], cytokeratin-19 fragment [CYFRA 21-1], and the precursor form of surfactant protein B [Pro-SFTPB]). The biomarker score was subsequently validated blindly using absolute risk estimates among 63 ever-smoking patients with lung cancer diagnosed within one year after blood collection and 90 matched controls from two large European population-based cohorts.

In the validation study of 63 ever-smoking patients with lung cancer and 90 matched controls (age, 57.7 ± 8.7 years; 68.6% men) from the cohorts, an integrated risk prediction model that combined smoking exposure with the biomarker score yielded an AUC of 0.83 (95% CI, 0.76-0.90) compared with 0.73 (95% CI, 0.64-0.82) for a model based on smoking exposure alone. With an overall specificity of 0.83, based on the US Preventive Services Task Force (USPSTF) screening criteria, the sensitivity of the integrated risk model was 0.63 compared to 0.43 for the smoking model. Additionally, at an overall sensitivity of 0.41 the integrated risk model yielded a specificity of 0.95 compared with 0.86 for the smoking model, based on the USPSTF screening criteria.

The authors concluded that these improvements in sensitivity and specificity were consistently observed across each evaluated stratum. Their findings also indicated that the improvement in discrimination afforded by the biomarker score is more modest beyond the initial year after blood draw, which suggests that an annual biomarker test may be necessary in a screening program. The study was published on July 12, 2018, in the journal JAMA Oncology.

Related Links:
International Agency for Research on Cancer

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.